Pfizer in Deal With Theraclone for Antibody Drug Research
Tuesday, January 18, 2011 - 18:20
in Mathematics & Economics
The deal, worth up to $632 million, is part of Pfizer’s effort to keep up with rivals that are increasingly relying on biotechnology for products and profits.